Atea Pharmaceuticals Inc Stock News

BOSTON, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a virtual key opinion leader (KOL) event on Thursday, November 13, 2025 at 10:00 AM ET to discuss a wide range of hep...

BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that new data will be presented supporting the combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor and ruzas...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT Company Participants Janet Hammond - Chief Development Officer Maria Horga - Chief Medical Officer John Vavricka - Chief Commercial Officer Andrea Corcoran - CFO, Executive VP of Legal & Secretary Conference Call Participants Maxwell Skor - Morgan Stanley, Research Div...

BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Confe...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andrea J. Corcoran - CFO, Executive VP of Legal & Secretary Janet M.

Atea (AVIR) Q2 Loss Narrows 8%

Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV  Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Confirming 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration Regimen of Bemnifosbuvir/Ruzasvir has Potential Best-in-Class Profile with Short Tre...

BOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to report financial results for...